CiMaas is developing cancer targeting immunotherapies. CiMaas lead products includes dendritic cell vaccine and natural killer (NK) cells for adoptive transfer that are obtained from healthy donors.
CiMaas is spin-off of the Maastricht University Medical Center (MUMC+) on the basis of a Proof of Concept loan of the Valorization Fund Zuid-Limburg (VPZL) and two Proof of Principle grants of the Limburg Business Development Fund (LBDF).
CiMaas is developing cancer targeting immunotherapies. CiMaas lead products includes dendritic cell vaccine and natural killer (NK) cells for adoptive transfer that are obtained from healthy donors.
CiMaas is spin-off of the Maastricht University Medical Center (MUMC+) on the basis of a Proof of Concept loan of the Valorization Fund Zuid-Limburg (VPZL) and two Proof of Principle grants of the Limburg Business Development Fund (LBDF).
CiMaas vaccine technology is based on activating autologous dendritic cells, using a proprietary ex vivo maturation process. After activation, the dendritic cells are transiently transfected with mRNA encoding the tumor antigen WT-1, to initiate a strong, tumor specific immune response after reintroduction into the patient.
CiMaas NK cell expansion technology utilizes an optimized NK cell expansion technology capable of producing up to 1010 NK cells.
In Jan 2017, CiMass received its first undisclosed funding. Key investors includes, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V.
Recover your password.
A password will be e-mailed to you.